Pegaptanib for the treatment of age-related macular degeneration.
暂无分享,去创建一个
[1] P. D. de Jong,et al. Increased expression of angiogenic growth factors in age-related maculopathy , 1997, The British journal of ophthalmology.
[2] J. Nordmann,et al. Vision-related quality of life in patients suffering from age-related macular degeneration. , 2005, American journal of ophthalmology.
[3] Hong Sun,et al. Plasma 8-isoprostane concentrations in patients with age-related cataracts. , 2005, Clinical chemistry.
[4] Napoleone Ferrara,et al. Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.
[5] H. Kaplan,et al. Pathogenesis of age-related macular degeneration. , 2004, Trends in molecular medicine.
[6] C. Gonzales. ENHANCED EFFICACY ASSOCIATED WITH EARLY TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PEGAPTANIB SODIUM: An Exploratory Analysis , 2005, Retina.
[7] E. Gragoudas,et al. Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.
[8] Joyce Nelson,et al. Pharmacokinetics and Safety of an Anti-Vascular Endothelial Growth Factor Aptamer (NX1838) Following Injection into the Vitreous Humor of Rhesus Monkeys , 2000, Pharmaceutical Research.
[9] P. Campochiaro,et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis. , 2004, American journal of ophthalmology.
[10] Y. Zou,et al. Genistein suppressed upregulation of vascular endothelial growth factor expression by cobalt chloride and hypoxia in rabbit retinal pigment epithelium cells. , 2003, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[11] B. Sullenger,et al. Aptamers: an emerging class of therapeutics. , 2005, Annual review of medicine.
[12] M. Matsumura,et al. Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy , 2004, British Journal of Ophthalmology.
[13] Christopher J. Robinson,et al. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. , 2001, Journal of cell science.
[14] Sheela M. Waugh,et al. 2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165) , 1998, The Journal of Biological Chemistry.
[15] S. Vinores. Technology evaluation: pegaptanib, Eyetech/Pfizer. , 2003, Current opinion in molecular therapeutics.
[16] A. Schachat. New treatments for age-related macular degeneration. , 2005, Ophthalmology.
[17] P. Jong. Prevalence of age-related macular degeneration in the United States. , 2004 .
[18] D. Hanahan,et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. , 2003, The Journal of clinical investigation.
[19] M. Siddiqui,et al. Pegaptanib: in exudative age-related macular degeneration. , 2005, Drugs.
[20] E. Ng,et al. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. , 2005, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.
[21] Joan W. Miller,et al. Anti-Vascular Endothelial Growth Factor Strategies for the Treatment of Choroidal Neovascularization From Age-Related Macular Degeneration , 2004, International ophthalmology clinics.
[22] N. Janjić,et al. Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro , 1999, In Vitro Cellular & Developmental Biology - Animal.
[23] D. Shima,et al. THE ROLE OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN OCULAR HEALTH AND DISEASE , 2005, Retina.
[24] Manju Patel,et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. , 2005, Ophthalmology.
[25] G. Vrensen,et al. Vascular endothelial growth factors and angiogenesis in eye disease , 2003, Progress in Retinal and Eye Research.
[26] John I. Loewenstein,et al. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. , 2003, Ophthalmology.
[27] S. Seregard,et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. , 1996, Investigative ophthalmology & visual science.
[28] H. Limburg,et al. CATARACT SURGICAL COVERAGE: An indicator to measure the impact of cataract intervention programmes. , 1998, Community eye health.
[29] Keryn A Williams,et al. Inhibitors of ocular neovascularization: promises and potential problems. , 2005, JAMA.
[30] J. Folkman,et al. Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.
[31] L. Aiello,et al. RISKS OF INTRAVITREOUS INJECTION: A COMPREHENSIVE REVIEW , 2004, Retina.
[32] R. Glickman,et al. Possible therapy for age-related macular degeneration using human telomerase , 2004, Brain Research Bulletin.
[33] Lawrence A. Yannuzzi,et al. PRECLINICAL AND PHASE 1A CLINICAL EVALUATION OF AN ANTI-VEGF PEGYLATED APTAMER (EYE001) FOR THE TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION , 2002, Retina.
[34] B Thylefors,et al. A global initiative for the elimination of avoidable blindness. , 1998, Community eye health.
[35] Joan W. Miller,et al. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. , 2003, Investigative ophthalmology & visual science.
[36] Joan W. Miller,et al. Aptamers, Intramers, and Vascular Endothelial Growth Factor , 2004, International ophthalmology clinics.